secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002859
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem secures up to $150M from Oberland Capital, repays Oxford loan, NDA accepted with June PDUFA
--------------------------------------------------------------------------------

- Initial $75M notes issued; net proceeds~$32.3M after repaying $42.7M Oxford loan; interest-only 6 years.
- Pro forma cash $128.6M including $7.5M equity placement (1.4M shares at $5.2931/share).
- FDA accepted NDA for avutometinib+defactinib in KRAS mutant LGSOC; PDUFA June 30, 2025; no AdCom planned.
- Revenue participation: Oberland gets 1% of first $100M annual net sales (max 2% if full $150M drawn).
- Strategic collaboration with IQVIA to support potential launch mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/0001104659-25-002859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/tm253090d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer